Bezard and colleagues [1] have to be congratulated on their studies and discussions of the mechanisms involved in compensation of striatal dopamine loss in Parkinson's disease (PD). To understand how PD begins and progresses is a major requirement in developing more definitive therapies for PD (A.E. Lang and J.A. Obeso, unpublished). Bezard et al. have conclusively shown that classically accepted dopamine-mediated mechanisms are not primarily involved in the initial compensation of striatal dopamine depletion in PD [1]. They proposed a series of functional compensatory changes within and outside the basal ganglia. We would like to discuss an alternative hypothesis for the onset of PD and the role of compensatory changes. Before that, some methodological comments are also pertinent. The Bordeaux group has established an N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model that provokes a full parkinsonian syndrome within three weeks, unlike PD, which develops over several years. Importantly, PD has a unilateral or asymmetrical onset whereas MPTP-intoxicated monkeys exhibited bilateral symptoms from the beginning. Both differential features of the model are relevant when analysing the onset of PD and initial compensatory mechanisms.
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We propose that cell loss occurs asymmetrically in the substantia nigra pars compacta (SNc) in the initial, presymptomatic stage. This leads to a reduction in the dopamine-mediated innervation and functional modulation of the subthalamic nucleus (STN) (Figure 1a ,b), inducing STN neuronal hyperactivity before significant dopamine striatal depletion [2, 3] . At this time (in the presymptomatic state), dopamine loss in the caudal putamen is still not large enough (, 50%) to increase activity in the striatal inhibitory projection to the globus pallidus pars externa (GPe). As a result, increased STN activity exerts a powerful excitatory effect on the GPe. Excitation of the GPe leads to increased inhibition of the globus pallidus pars interna (GPi) and maintains the output of the motor circuit within normal limits. In that fashion, the 'internal' STN -GPe -GPi circuit compensates itself [4] . Increased STN activity could increase GPi firing by its direct excitatory projection [5] but this can be compensated by the still-normal 'direct' striatopallidal (i.e. to the GPi) inhibitory projection. As the neurodegenerative process progresses, striatal dopamine deficit becomes high enough (i.e. 70%) to inhibit the GPe, diminishing its inhibitory output onto the GPi and STN (Figure 1c) . At this stage, the compensatory mechanisms keeping the GPi output activity within normal limits fail and, consequently, the STN -GPi circuit becomes pathologically overactive and parkinsonian symptoms are clinically obvious. In PD, where the changes occur slowly, excessive STN drive onto the GPi might also be compensated by way of the nigropallidal dopaminergic projection, which has been shown by fluorodopa positron emission tomography (PET) to increase during the presymptomatic phase [6] . In addition, the contralateral hemisphere probably plays an essential compensatory role, so that abnormal GPi output onto the thalamocortical projection can be compensated by the still-normally-operating basal ganglia. This is supported by PET data showing a 36% reduction in fluorodopa uptake by the hemisphere contralateral to the clinically unaffected caudal putamen in recently diagnosed patients (i.e. what appears to be normal on clinical grounds is shown to be abnormal by PET). It appears that clinical manifestation requires not only derangement of basal ganglia mechanisms in the primary affected side but also dopamine depletion in the secondarily affected side. Our interpretation does not completely fit with the physiological data of Bezard et al.
[3], particularly the lack of change in firing rate of GPe neurons throughout MPTP administration. However, physiological studies in chronically intoxicated MPTP monkeys and PD patients have shown reduced neuronal firing in the GPe [7] . The major limitation of our hypothesis is basing the origin of the initial stages of PD on the hyperactivity of the STN and its disinhibition by a direct dopamine deficit. It could be that parallel derangement of several dopaminergic projections occurs quasi-simultaneously. Given the large cellular heterogeneity of the substantia nigra [8] , early degeneration of especially vulnerable dopaminergic neurons that reach the motor putamen but that also branch, via axon collaterals, within the STN, globus pallidus and other glutamatergic nuclei (e.g. the pedunculopontine and centromedian-parafascicular nuclei), could be responsible for the hitherto unexplained increased in STN activity preceding striatal dopamine depletion. Appropriate definition of the relevance of the different compensatory mechanisms is very important for promoting new treatments for PD. This could be feasible by using a methodology similar to the one 
